Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine and Fentanyl for Transurethral Prostatectomy in Elderly Patients
NCT03704441Completed
- Sponsor
- Hallym University Kangnam Sacred Heart Hospital
- Start
- Nov 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of bupivacaine in benign prostatic hyperplasia (BPH) (7 arms), sponsored by Hallym University Kangnam Sacred Heart Hospital. Primary endpoints: Median Effective Dose at 2 years and 95% Effective Dose at 2 years. Started Nov 2018; status: completed.
02
Drugs
bupivacaine
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT03704441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03704441.